Peptide Profile

KPV

Lys-Pro-Val Tripeptide

Research Only10 sourcesShop KPV

Overview

Composition

Synthetic tripeptide (three-amino-acid sequence: Lysine-Proline-Valine) derived from the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH)

Mechanism of Action

Interacts with melanocortin receptors and pathways, inhibiting NF-κB and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), reducing oxidative stress, and supporting epithelial barrier integrity

Primary Effects

Studied for anti-inflammatory, immunomodulatory, antimicrobial, and epithelial-barrier effects, mostly in cell and animal models

Discovery & Background

Identified in late 1990s-early 2000s during research on α-MSH anti-inflammatory mechanisms, isolating the C-terminal tripeptide (Lys-Pro-Val) as the core sequence

Early work focused on melanocortin signaling for immune modulation. Studies in 2000s demonstrated efficacy in inflammation models, leading to exploration in IBD, skin disorders, and wound healing

Not FDA-approved; remains research/investigational, often compounded or used off-label

Research Overview

Evidence primarily from preclinical models (cell cultures, rodents) showing KPV reduces inflammation via NF-κB/MAPK inhibition and enhances gut barrier function

01
Cytokine downregulation (TNF-α, IL-1β, IL-6)
02
Enhanced gut barrier function in colitis models
03
Antimicrobial activity against Staphylococcus aureus and Candida albicans
04
Animal colitis models (DSS-, TNBS-induced) show reduced disease severity, improved mucosal healing
05
Controlled human efficacy data are still sparse
06
Targeted anti-inflammatory claims remain preclinical and should not be equated with established steroid-sparing therapy

No FDA approval for any indication; lacks large-scale RCTs. Human outcome data are sparse, and wellness-community reports are uncontrolled

Safety Considerations

Monitoring

Inflammation markers
Symptom tracking (pain, digestive function, skin condition)
Response to treatment
Tolerance assessment

Side Effects

General

Generally well-tolerated with minimal reported side effects
Preclinical safety profile shows minimal toxicity

Data limitations

Human adverse-event reporting is not well standardized
Long-term immune and microbiome effects remain uncertain

Contraindications

Hypersensitivity to KPV or components
Unknown interactions due to limited human data
Variable quality in compounded forms

Educational Notice

KPV lacks approval from major regulatory bodies for human therapeutic use and remains investigational. Controlled human safety and efficacy data are limited, while most support comes from mechanistic and preclinical inflammation research. Potential risks, interactions, and compounded-product variability are not fully characterized, so clinical decisions require qualified medical oversight.

References